NCT06632951 2025-08-11
LIVIGNO-3
AbbVie
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT01215136 2023-11-24
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT02581982 2023-01-10
Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT02109328 2019-04-11
Alisertib in Chemotherapy-pretreated Urothelial Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT03745911 2018-11-19
Paclitaxel and TAK-228 in Urothelial Carcinoma
Associació per a la Recerca Oncologica, Spain
Phase 2 Unknown
NCT00683059 2016-10-17
Single Agent Abraxane as Second Line Therapy in Bladder Cancer
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT00154687 2007-07-31
Weekly TP-HDFL in the Treatment of Advanced TCC
National Taiwan University Hospital
Phase 2 Completed